IP Verse

Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna - EP4066857

The patent EP4066857 was granted to Glaxosmithkline on Dec 21, 2022. The application was originally filed on Aug 31, 2011 under application number EP22174932A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4066857

GLAXOSMITHKLINE
Application Number
EP22174932A
Filing Date
Aug 31, 2011
Status
Granted And Under Opposition
Nov 18, 2022
Grant Date
Dec 21, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JG OPPOSITIONSSep 21, 2023MEWBURN ELLISADMISSIBLE
THOMANNSep 21, 2023THOMANNADMISSIBLE
WEICKMANN & WEICKMANNSep 20, 2023WEICKMANN & WEICKMANN PARTMBBADMISSIBLE
SANOFISep 19, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP3981427
OPPOSITIONEP4066857
OPPOSITIONWO2005007689
OPPOSITIONWO2005120152
OPPOSITIONWO2005121348
OPPOSITIONWO2007047749
OPPOSITIONWO2011005799
OPPOSITIONWO2011068810
OPPOSITIONWO2012006369
OPPOSITIONWO2012006376
OPPOSITIONWO2012006377
OPPOSITIONWO2012006378
OPPOSITIONWO2012030901
OPPOSITIONWO2012031043
OPPOSITIONWO2014160243
OPPOSITIONWO2017049245
OPPOSITIONWO2017075531
OPPOSITIONWO2018075980
OPPOSITIONWO2022137133
SEARCHWO2008103276
SEARCHWO2009086558
SEARCHWO2009111088
SEARCHWO2011005799

Non-Patent Literature (NPL) Citations (65) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BOXUS et al., J Virol, (20070000), vol. 81, pages 6879 - 89-
DESCRIPTION- EL OUAHABI et al., FEBSLetts, (19960000), vol. 380, pages 108 - 12-
DESCRIPTION- "Functional Polymer Colloids and Microparticles", Microspheres, microcapsules & liposomes, Citus Books, (20020000), vol. 4-
DESCRIPTION- GIULIANI et al., Proc Natl Acad Sci USA, (20060000), vol. 1, 2, 3, no. 29, pages 10834 - 9-
DESCRIPTION- Handbook of Experimental Immunology, Blackwell Scientific Publications, (19860000), vol. I-IV-
DESCRIPTION- HEYES et al., J Controlled Release, (20050000), vol. 107, pages 276 - 87-
DESCRIPTION- HOEKSTRA et al., Biochimica et Biophysica Acta, (20040000), vol. 1660, pages 41 - 52-
DESCRIPTION- JEFFS et al., Pharmaceutical Research, (20050000), vol. 22, no. 3, pages 362 - 372-
DESCRIPTION- JOHANNING et al., Nucleic Acids Res, (19950000), vol. 23, pages 1495 - 1501-
DESCRIPTION- "Liposomes: Methods and Protocols", Pharmaceutical Nanocarriers: Methods and Protocols, Humana Press, (20090000), vol. 1-
DESCRIPTION- MAURER et al., Biophysical Journal, (20010000), vol. 80, pages 2310 - 2326-
DESCRIPTION- PERRI et al., J Virol, (20030000), vol. 77, pages 10394 - 10403-
DESCRIPTION- ROMBERG et al., Pharmaceutical Research, (20080000), vol. 25, pages 55 - 71-
DESCRIPTION- TAYLOR et al., Vaccine, (20050000), vol. 23, pages 1242 - 50-
DESCRIPTION- YONEYAMAFUJITA, Cytokine & Growth Factor Reviews, (20070000), vol. 18, pages 545 - 51-
OPPOSITION- Anonymous, "Passage; Medical Virology", Anonymous, White David O, Fenner Frank J, Medical Virology Fourth Edition, Academic Press, (19940101), page 3-29, 434-435, 450-459, 538-541, ISBN 0-12-746642-8, XP093046091-
OPPOSITION- Anonymous, "Spikevax1 (COVID-19 mRNA Vaccine (nucleoside modified))", European Medicines Agency ; Science Medicine Health, (20221001), pages 1 - 5, XP093134302-
OPPOSITION- Bernstein, D.I. ; Reap, E.A. ; Katen, K. ; Watson, A. ; Smith, K. ; Norberg, P. ; Olmsted, R.A. ; Hoeper, A. ; Morris, J. ; Negri, S. ; Maughan, M.F. ; Chulay, J.D., "Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20091211), vol. 28, no. 2, ISSN 0264-410X, pages 484 - 493, XP026791388-
OPPOSITION- Dolgin Elie, "Trial settles debate over best design for mRNA in covid vaccines", Nature, (20230119), vol. 613, pages 419 - 420, XP093134290-
OPPOSITION- Immordino et al., "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", Intl. J. Nanomed., (2006), vol. 1, XP009145524-
OPPOSITION- Immordino Maria Laura, Dosio Franco, Cattel Luigi, "Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential", International Journal of Nanomedicine, AUCKLAND, NZ , (20060101), vol. 1, no. 3, ISSN 1176-9114, pages 297 - 315, XP093134285-
OPPOSITION- Lowe Derek, "CureVac Comes Around", (20230126), pages 1 - 5, Science , URL: https://www.science.org/content/blog-post/curevac-comes-around, (20240223), XP093134298-
OPPOSITION- MacLachlan, Ian, "Chapter 9: Liposomal Formulations for Nucleic Acid Delivery", MacLachlan, Ian, CROOKE STANLEY T, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2ND ED., US , CRC PRESS , (20070725), pages 237 - 270, ISBN 978-0-8493-8796-8, XP055915899-
OPPOSITION- Thomas C. Heineman, "Chapter 71 Human cytomegalovirus vaccines", Thomas C. Heineman, Arvin A, Campadelli-Fiume G, Mocarski E, Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, (2007011)-
OPPOSITION- Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Steve Pascolo, Shayne Cox, Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043
OPPOSITION- F Martinon , S Krishnan, G Lenzen, R Magné, E Gomard, J G Guillet, J P Lévy, P Meulien, "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", European Journal of Immunology, Hoboken, USA, (19930101), vol. 23, doi:10.1002/eji.1830230749, ISSN 0014-2980, pages 1719 - 1722, XP002937540
OPPOSITION- Martinon et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", Eur. J. Immunol., (1993), vol. 23, doi:10.1002/eji.1830230749, XP002937540
OPPOSITION- Li et al., "Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery", Journal of Gene Medicine, (2005), vol. 7, doi:10.1002/JGM.634, XP008126013
OPPOSITION- Morrison Trudy G., "Paramyxoviruses, Infection and Immunity", Encyclopedia of immunology, San Diego, (19980101), doi:10.1006/rwei.1999.0481, ISBN 978-0-12-226765-9, pages 1909 - 1916, XP093133676
OPPOSITION- Jeffs et al., "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (2005), vol. 22, doi:10.1007/s11095-004-1873-z, page 3, XP019370801
OPPOSITION- Jeffs et al., "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, (2005), vol. 22, doi:10.1007/s11095-004-1873-z, XP019370801
OPPOSITION- Lloyd B. Jeffs ; Lorne R. Palmer ; Ellen G. Ambegia ; Cory Giesbrecht ; Shannon Ewanick ; Ian MacLachlan, "A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA", Pharmaceutical Research, NL , (20050301), vol. 22, no. 3, doi:10.1007/s11095-004-1873-z, ISSN 1573-904X, pages 362 - 372, XP019370801
OPPOSITION- Klibanov, A.L. ; Maruyama, K. ; Torchilin, V.P. ; Huang, L., "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes", FEBS Letters, NL , (19900730), vol. 268, no. 1, doi:10.1016/0014-5793(90)81016-H, ISSN 0014-5793, pages 235 - 237, XP025890437
OPPOSITION- Wilson et al., "The Introduction of Poliovirus RNA into Cells via Lipid Vesicles (Liposomes)", Cell, (1979), vol. 17, doi:10.1016/0092-8674(79)90296-4, XP023910555
OPPOSITION- X. Zhou , P. Berglund , G. Rhodest, S.E. Parker, M. Jondalt , P. Liljestrom, "Self-replicating Semliki Forest virus RNA as recombinant vaccine", Vaccine, (19940101), vol. 12, no. 16, pages 1510 - 1514, XP093134288
OPPOSITION- Minnaert et al., "Strategies for controlling the innate immuneactivity of conventional and self-amplifying mRNA therapeutics: Getting the message across .", Advanced Drug Discovery Reviews, (2021), vol. 176, doi:10.1016/j.addr.2021.113900, XP086773295
OPPOSITION- Adriana O. Santos et al, "Design of peptide-targeted liposomes containing nucleic acids", Biochimica et Biophysica Acta, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100301), vol. 1798, no. 3, doi:10.1016/J.BBAMEM.2009.12.001, ISSN 0005-2736, pages 433 - 441, XP002665487
OPPOSITION- Kim et al., "Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid", International Journal of Pharmaceutics, (2010), vol. 392, XP027044515
OPPOSITION- Schoenmaker Linde, Witzigmann Dominik, Kulkarni Jayesh A., Verbeke Rein, Kersten Gideon, Jiskoot Wim, Crommelin Daan J.A., "mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability", International Journal of Pharmaceutics, NL , (20210501), vol. 601, doi:10.1016/j.ijpharm.2021.120586, ISSN 0378-5173, pages 1 - 13, XP055828800
OPPOSITION- Heyes et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J Controlled Release, (2005), vol. 107, doi:10.1016/j.jconrel.2005.06.014, XP008157522
OPPOSITION- Heyes et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. Controlled Release, (2005), vol. 107, doi:10.1016/j.jconrel.2005.06.014, XP008157522
OPPOSITION- Heyes, J. Palmer, L. Bremner, K. MacLachlan, I., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", Journal of Controlled Release, AMSTERDAM, NL , (20051003), vol. 107, no. 2, doi:10.1016/j.jconrel.2005.06.014, ISSN 0168-3659, pages 276 - 287, XP005076220
OPPOSITION- Obata et al., "Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo", J. Controlled Release , (2010), vol. 142, doi:10.1016/j.jconrel.2009.10.023, XP026905290
OPPOSITION- Hassett Kimberly J., Benenato Kerry E., Jacquinet Eric, Lee Aisha, Woods Angela, Yuzhakov Olga, Himansu Sunny, Deterling Jessica, Geilich Benjamin M., Ketova Tatiana, Mihai Cosmin, Lynn Andy, Mcfadyen Iain, Moore Melissa J., Senn Joseph J., Stanton Matthew G., Almarsson Örn, Ciaramella Giuseppe, Brito Luis A., "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines", Molecular Therapy-Nucleic Acids, US , (20190415), vol. 15, doi:10.1016/j.omtn.2019.01.013, ISSN 2162-2531, pages 1 - 11, XP055815007
OPPOSITION- Kimberly J. Hassett et al., "Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines", Mol Ther Nucleic Acids, (2019), vol. 15, doi:10.1016/j.omtn.2019.01.013, XP055815007
OPPOSITION- Geall Andrew J.; Mandl Christian W.; Ulmer Jeffrey B., "RNA: The new revolution in nucleic acid vaccines", Seminars in immunology, W.B. SAUNDERS COMPANY, PA., US, US , (19000101), vol. 25, no. 2, doi:10.1016/j.smim.2013.05.001, ISSN 1044-5323, pages 152 - 159, XP028694558
OPPOSITION- Ulmer et al., "RNA-based vaccines", Vaccine, (2012), vol. 30, doi:10.1016/j.vaccine.2012.04.060, XP028520925
OPPOSITION- Karikó Katalin, Muramatsu Hiromi, Welsh Frank A, Ludwig János, Kato Hiroki, Akira Shizuo, Weissman Drew, "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability /NIH Author Manuscript/", Molecular Therapy, US , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0016, pages 1833 - 1840, XP055920956
OPPOSITION- Zimmermann Tracy S., Lee Amy C. H., Akinc Akin, Bramlage Birgit, Bumcrot David, Fedoruk Matthew N., Harborth Jens, Heyes James A., Jeffs Lloyd B., John Matthias, Judge Adam D., Lam Kieu, Mcclintock Kevin, Nechev Lubomir V., Palmer Lorne R., Racie Timothy, Röhl Ingo, Seiffert Stephan, Shanmugam Sumi, Sood Vandana, Soutschek Jürgen, Toudjarska Ivanka, Wheat Amanda J., Yaworski Ed, Zedalis William, Koteliansky Victor, Manoharan Muthiah, Vornlocher Hans-Peter, Maclachlan Ian, "RNAi-mediated gene silencing in non-human primates", Nature, (20060101), vol. 441, doi:10.1038/nature04688, ISSN 0028-0836, pages 111 - 114, XP093134286
OPPOSITION- Petsch et al., "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", Nature Biotechnology, (2012), vol. 30, doi:10.1038/nbt.2436, page 12, XP055051005
OPPOSITION- Sahin et al., "mRNA-based therapeutics - developing a new class of drugs", Nature Reviews Drug Discovery, (2014), vol. 13, doi:10.1038/nrd4278, XP055544673
OPPOSITION- Akinc Akin; Maier Martin A.; Manoharan Muthiah; Fitzgerald Kevin; Jayaraman Muthusamy; Barros Scott; Ansell Steven; Du Xinyao; Hope Michael J.; Madden Thomas D.; Mui Barbara L.; Semple Sean C.; Tam Ying K.; Ciufolini Marco; Witzigmann Dominik; Kulkarni Jayesh A.; van der Meel Roy; Cullis Pieter R., "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs", Nature Nanotechnology, London , (20191201), vol. 14, no. 12, doi:10.1038/s41565-019-0591-y, ISSN 1748-3387, pages 1084 - 1087, XP036953174
OPPOSITION- Norbert Pardi , Michael J Hogan , Martin S Naradikian , Kaela Parkhouse , Derek W Cain , Letitia Jones , M Anthony Moody , Hans P Verkerke , Arpita Myles , Elinor Willis , Celia C LaBranche , David C Montefiori , Jenna L Lobby , Kevin O Saunders , Hua-Xin Liao , Bette T Korber , Laura L Sutherland , Richard M Scearce , Peter T Hraber, István Tombácz , Hiromi Muramatsu , Houping Ni, Daniel A Balikov , Charles Li , Barbara L Mui , Ying K Tam , Florian Krammer , Katalin Karikó , Patricia Polacino , Laurence C Eisenlohr , Thomas D Madden , Michael J Hope , Mark G Lewis , Kelly K Lee , Shiu-Lok Hu , Scott E Hensley , Michael P Cancro , Barton F Haynes , Drew Weissman, "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses", Journal of Experimental Medicine, US , (20180604), vol. 215, no. 6, doi:10.1084/jem.20171450, ISSN 0022-1007, pages 1571 - 1588, XP055545604
OPPOSITION- Fleeton et al., "Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus", The Journal of Infectious Diseases, (2001), vol. 183, doi:10.1086/319857, XP002224503
OPPOSITION- W Z Zhou , D S Hoon, S K Huang, S Fujii, K Hashimoto, R Morishita, Y Kaneda, "RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.", Human Genen Therapy, GB , (19991101), vol. 10, no. 16, doi:10.1089/10430349950016762, ISSN 1043-0342, pages 2719 - 2724, XP002660042
OPPOSITION- Sonoke et al., "Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes", Cancer Research , (2008), vol. 68, doi:10.1158/0008-5472.CAN-08-0127, XP055046252
OPPOSITION- Group Francis, "CHAPTER 9. Liposomal Formulations for Nucleic Acid Delivery", Antisense Drug Technology, Second Edition, CRC Press, (20070101), pages 237 - 270, XP093133162
OPPOSITION- Ian Maclachlan, "Liposomal Formulations for Nucleic Acid Delivery", Ian Maclachlan, Stanley T. Crooke, Antisense Drug Technology : Principles, Strategies, and Applications, Second Edition, CRC Press , (20070725), pages 237 - 270, doi:10.1201/9780849387951.ch9, ISBN 978-1-4398-3250-9, XP055591157
OPPOSITION- Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, Humana Press, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840
OPPOSITION- Pascolo Steve, "Messenger RNA-based vaccines", Expert Opinion Biological Theraphy, (20040801), vol. 4, no. 8, doi:10.1517/14712598.4.8.1285, ISSN 1471-2598, pages 1285 - 1294, XP009095328
OPPOSITION- Deering Raquel P; Kommareddy Sushma; Ulmer Jeffrey B, "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.", Expert opinion on drug delivery, Informa Healthcare, UK, UK , (20140601), vol. 11, no. 6, doi:10.1517/17425247.2014.901308, ISSN 1744-7593, pages 885 - 899, XP009183535
OPPOSITION- Morais Pedro, Adachi Hironori, Yu Yi-Tao, "The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines", Frontiers in Cell and Developmental Biology, (20211101), vol. 9, doi:10.3389/fcell.2021.789427, pages 1 - 9, XP055885272
OPPOSITION- Karl-Josef Kallen, Regina Heidenreich, Margit Schnee, Benjamin Petsch, Thomas Schlake, Andreas Thess, Patrick Baumhof, Birgit Scheel, Sven D Koch, Mariola Fotin-Mleczek, "A novel, disruptive vaccination technology: Self-adjuvanted RNActive® vaccines", Human vaccines & immunotherapeutics, (20131001), vol. 9, no. 10, doi:10.4161/hv.25181, ISSN 21645515, pages 2263 - 2276, XP055126357
OPPOSITION- Schlake et al., "Developing mRNA-vaccine technologies", RNA Biology, (2012), vol. 9, doi:10.4161/rna.22269, page 11, XP055126360
SEARCH- MOCKEY M ET AL, "mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes", CANCER GENE THERAPY, (200709), vol. 14, no. 9, ISSN 0929-1903, pages 802 - 814, XP055007324 [A] 1-20 * page 804, column l, paragraph 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents